Ambu A/S (FRA:547A)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.35B -44.2% |
| Revenue (ttm) | 814.76M +7.8% |
| Net Income | 72.84M +66.9% |
| EPS | 0.27 +67.9% |
| Shares Out | n/a |
| PE Ratio | 32.21 |
| Forward PE | 25.38 |
| Dividend | 0.05 (0.59%) |
| Ex-Dividend Date | Dec 4, 2025 |
| Volume | n/a |
| Average Volume | 15 |
| Open | 8.67 |
| Previous Close | 8.92 |
| Day's Range | 8.67 - 8.67 |
| 52-Week Range | 8.54 - 16.09 |
| Beta | n/a |
| RSI | 44.44 |
| Earnings Date | May 6, 2026 |
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also prov... [Read more]
Financial Performance
In fiscal year 2025, Ambu A/S's revenue was 6.04 billion, an increase of 11.98% compared to the previous year's 5.39 billion. Earnings were 609.00 million, an increase of 159.15%.
Financial numbers in DKK Financial StatementsNews
ANNUAL REPORT 2022/23 (EARNINGS RELEASE)
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S...